Showing results (161-170 of 559) with videos related to
Sort By:
Pageof 56
American Heart Journal|October 3, 2002
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapyBrad G Angeja, James de Lemos, Sabina A Murphy, et al.American Heart Journal|June 21, 2002
Identification of patients at high risk for death and cardiac ischemic events after hospital dischargeMarc S Sabatine, Carolyn H McCabe, David A Morrow, et al.Journal of the American College of Cardiology|August 29, 2020
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System AntagonistsAndrew P Ambrosy, Eugene Braunwald, David A Morrow, et al.The American Journal of Cardiology|November 30, 2004
Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarctionMinang P Turakhia, Sabina A Murphy, Tina L Pinto, et al.Hypertension (Dallas, Tex. : 1979)|July 30, 2019
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 TrialSungha Park, Brian A Bergmark, Minggao Shi, et al.Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|April 24, 2016
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic SubstudyDeepak K Gupta, Robert P Giugliano, Christian T Ruff, et al.European Heart Journal|December 28, 2018
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trialTze-Fan Chao, Shih-Ann Chen, Christian T Ruff, et al.JAMA Cardiology|October 6, 2016
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.The American Journal of Cardiology|July 13, 2004
Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteriesGraham S Gardner, Daniel R Frisch, Sabina A Murphy, et al.American Heart Journal|May 17, 2011
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndromeC Michael Gibson, Jessica L Mega, Paul Burton, et al.Pageof 56